Site Alert

Claim & Account Center and Secure Message Center are currently experiencing intermittent slowdowns. We are working to resolve this issue as soon as possible. We apologize for any inconvenience.

Coverage Decisions for Drugs

Carisoprodol

Coverage decision

L&I does not cover carisoprodol products including combinations with aspirin and codeine. See the Preferred Drug List for safer alternatives.

Carisoprodol is a centrally acting skeletal muscle relaxant that does not directly relax tense skeletal muscles in man. It is metabolized in the liver to meprobamate, an anxiolytic and a federally controlled substance subject to physical dependence. The Washington State Pharmacy and Therapeutics Committee, after an evidence-based review of the skeletal muscle relaxants drug class, has recommended the removal of carisoprodol products from L&I’s formulary for safety reasons.

The Food and Drug Adminsitration (FDA) has approved the following carisoprodol products to relieve discomfort associated with acute, painful musculoskeletal conditions:

  • Soma® (carisoprodol).
  • Soma Compound® (carisoprodol with aspirin).
  • Soma Compound with Codeine® (carisoprodol with aspirin and codeine).

End of main content, page footer follows.

Access Washington official state portal

  © Washington State Dept. of Labor & Industries. Use of this site is subject to the laws of the state of Washington.

Help us improve